Inogen, Inc. (NASDAQ:INGN) Shares Sold by Divisadero Street Capital Management LP

Divisadero Street Capital Management LP reduced its position in shares of Inogen, Inc. (NASDAQ:INGN - Free Report) by 81.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 200,000 shares of the medical technology company's stock after selling 856,403 shares during the period. Divisadero Street Capital Management LP owned 0.84% of Inogen worth $1,834,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Barclays PLC boosted its position in Inogen by 72.9% during the third quarter. Barclays PLC now owns 55,508 shares of the medical technology company's stock worth $539,000 after acquiring an additional 23,398 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Inogen during the third quarter worth $111,000. JPMorgan Chase & Co. grew its position in shares of Inogen by 2.7% in the third quarter. JPMorgan Chase & Co. now owns 896,106 shares of the medical technology company's stock valued at $8,692,000 after purchasing an additional 23,891 shares during the period. Ieq Capital LLC acquired a new position in Inogen in the fourth quarter valued at $94,000. Finally, Bank of New York Mellon Corp lifted its position in Inogen by 23.5% during the fourth quarter. Bank of New York Mellon Corp now owns 126,461 shares of the medical technology company's stock worth $1,160,000 after buying an additional 24,082 shares during the period. 89.94% of the stock is currently owned by hedge funds and other institutional investors.

Inogen Stock Down 1.7 %

Shares of NASDAQ INGN traded down $0.11 during midday trading on Friday, hitting $6.24. The stock had a trading volume of 471,563 shares, compared to its average volume of 236,902. Inogen, Inc. has a 1-year low of $5.75 and a 1-year high of $13.33. The company has a market capitalization of $167.77 million, a price-to-earnings ratio of -2.77 and a beta of 1.63. The company has a fifty day moving average price of $7.17 and a 200 day moving average price of $8.91.

Inogen (NASDAQ:INGN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.27. Inogen had a negative net margin of 15.89% and a negative return on equity of 27.38%. The firm had revenue of $82.28 million for the quarter, compared to analyst estimates of $79.57 million. On average, research analysts forecast that Inogen, Inc. will post -1.73 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on INGN shares. Stifel Nicolaus dropped their price objective on shares of Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a research note on Thursday. Needham & Company LLC reaffirmed a "hold" rating on shares of Inogen in a research report on Wednesday, April 9th. Finally, StockNews.com downgraded shares of Inogen from a "buy" rating to a "hold" rating in a research note on Wednesday, February 26th.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.